Evidence map›Paper›PMID 28688287›Full record

ArticleBiomaterials2017

Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy.

Dandan Guo, Changying Shi, Xu Wang, Lili Wang, Shengle Zhang, Juntao Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. "Click" amphotericin B in prodrug nanoformulations for enhanced systemic fungemia treatment.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dandan GuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Changying ShiDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Xu WangDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Lili WangDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Shengle ZhangDepartment of Pathology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Juntao LuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address: luoj@upstate.edu.

Funding

Size-tunable cancer nanotherapeuticsR01CA140449 · NCI · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2010 to 2014
$1.6M
An innovative hemoperfusion nanotrap for sepsis treatment.R01GM130941 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2018 to 2021
$1.5M
Rational Design and High throughput synthesis of nanocarriers for efficient drug deliveryR21EB019607 · NIBIB · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2015 to 2016
$453k
NCI NIH HHS R01 CA140449NIBIB NIH HHS R21 EB019607
6 · The paper itself

Abstract

We have developed two linear-dendritic telodendrimers (TDs) with rational design using amphiphilic riboflavin (Rf) as building blocks for efficient doxorubicin (DOX) delivery. Micellar TD nanoparticles (NPs) are composed of a hydrophilic polyethylene glycol (PEG) shell and a Rf-containing affinitive core for DOX encapsulation. Strong DOX-Rf interactions and amphiphilic Rf structure render these nanocarriers with an ultra-high DOX loading capacity (>1/1, DOX/TD, w/w), ∼100% loading efficiency, the sustained drug release and the optimal particle sizes (20-40 nm) for efficient tumor-targeted drug delivery. These nanoformulations significantly prolonged DOX circulation time in the blood without the accelerated clearance observed after multiple injections. DOX-TDs target several types of tumors efficiently in vivo, e.g. Raji lymphoma, MDA-MB-231 breast cancer, and SKOV-3 ovarian cancer. In vivo maximum tolerated dose (MTD) of DOX was increased by 2-2.5 folds for the nanoformulations in mice relative to those of free DOX and Doxil

Indexed as

AnimalsAntibiotics, AntineoplasticCell Line, TumorDelayed-Action PreparationsDoxorubicinFemaleHumansMiceMice, Inbred BALB CNeoplasmsOvarian NeoplasmsRiboflavinSurface-Active AgentsAntibiotics, AntineoplasticDelayed-Action PreparationsDoxorubicinRiboflavinSurface-Active AgentsCancer treatmentControlled drug releaseHigh loading capacityRational nanocarrier designTargeted therapyTelodendrimer

Identifiers

PMID28688287
PMCPMC5557385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.